Effects of telmisartan on paroxysmal atrial fibrillation in hypertensive patients.
This study examined the effects and mechanisms of telmisartan in hypertensive patients with paroxysmal atrial fibrillation (PAF). Hypertensive patients with PAF (n=120) were randomized into test (telmisartan) and control (amlodipine besilate) groups. The pretreatment and post treatment left atrial dimension (LAD), high-sensitivity C-reactive protein (hs-CRP) levels, heart rate, blood pressure (BP), and recurrence times of atrial fibrillation (AF) were recorded. The pretreatment and post treatment heart rates and BPs did not differ in either group (P>0.05). The post treatment systolic BP (SBP) and diastolic BP (DBP) did not differ between the groups (SBP: test, 132±5mmHg; control, 133±6 mmHg; DBP: test, 82±4 mmHg; control, 83±4mmHg). The LAD (test, 36.7±5.1 mm; control, 31.3±4.1mm) and hs-CRP (test, 5.6±2.6mg/L; control, 3.1±1.9mg/L) levels declined significantly (P>0.05) after treatment in the telmisartan group but not in the control group. After treatment, the LAD (test, 31.3±4.1mm; control, 36.2±4.6mm), hs-CRP (test, 3.1±1.9 mg/L; control, 5.2±2.3mg/L) levels, and AF recurrence times were markedly lower in the test group (22) compared with the control group (44). Thus, telmisartan reduced the AF recurrence rates, LAD, and hs-CRP levels.